We show that administration of this peptide to NSCLC not only stabilizes PTPN23 to reactivate the lysosomal degradation of wild type and mutant EGFR and c-MET, but also induces potent anti-tumor effects on EGFR TKI-resistant NSCLC cells to suppress their growth in vitro and in vivo, survival, migration, invasion, and metastasis. The gene discussed is MET; the disease is non-small cell lung carcinoma.